Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.49
$0.9220.13%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -20.36% | -19.96% | 43.56% | 127.53% | 439.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.36% | -19.96% | 43.56% | 127.53% | 439.91% |
| Cost of Revenue | -60.46% | 43.81% | 22.36% | 46.93% | -308.89% |
| Gross Profit | 50.81% | -63.28% | -18.74% | -34.62% | 350.34% |
| SG&A Expenses | 39.75% | 49.83% | 33.45% | 2.99% | 17.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.30% | 45.36% | 25.54% | 31.83% | 14.77% |
| Operating Income | -56.95% | -59.09% | -23.45% | -22.71% | 1.80% |
| Income Before Tax | -68.82% | -53.89% | -17.03% | -16.70% | 11.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.75% | -53.89% | -17.03% | -16.70% | 11.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.75% | -53.89% | -17.03% | -16.70% | 11.46% |
| EBIT | -56.95% | -59.09% | -23.45% | -22.71% | 1.80% |
| EBITDA | -52.81% | -54.36% | -20.14% | -22.09% | 3.43% |
| EPS Basic | -34.59% | -24.53% | -0.05% | -3.93% | 19.25% |
| Normalized Basic EPS | -35.57% | -24.52% | -0.08% | -2.10% | 15.28% |
| EPS Diluted | -34.59% | -24.53% | -0.05% | -3.93% | 19.25% |
| Normalized Diluted EPS | -35.57% | -24.52% | -0.08% | -2.10% | 15.28% |
| Average Basic Shares Outstanding | 20.19% | 23.58% | 16.96% | 12.26% | 9.62% |
| Average Diluted Shares Outstanding | 20.19% | 23.58% | 16.96% | 12.26% | 9.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |